6 Alternative only for patients who are negative for the Q80K substitution by commercially available resistance assay. Other recommended or alternative regimens should be used for patients with genotype 1a compensated cirrhosis in whom the Q80K substitution is present.

7 Baseline RAS testing for Y93H is recommended. Ribavirin should be included in regimen or consider Vosevi if present.

8 12 weeks is recommended for patients who experience virologic relapse after PEG-IFN/ribavirin therapy. Patients with prior on-treatment virologic failure (failure to suppress or breakthrough) while on PEG-IFN/ribavirin should be treated with 16 weeks and have weight-based ribavirin added.